Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome.
Progressive multiorgan dysfunction syndrome may occur in the course of sepsis and septic shock as well as after various intoxications, pancreatitis, crush injuries, and major surgery. Despite conventional intensive care therapies, the prognosis in these patients is still poor. Apheresis, which uses more selective adsorption techniques, can lower the extent of toxins and cytokines in blood. This is achieved in clinical practice by, e.g., using polymyxin B as adsorbent. Although significantly lowered, the mortality is still about 50% with this technique. By unselective plasma exchange, the mortality is reduced down to 20 to 40%. A controlled and randomized study has shown a significant benefit. The centrifugation technique may be favorable over plasma filtration. Not only removal but also replacement with plasma seems important. In the future, probably selective techniques will be used in the early stages of sepsis while unselective plasma exchange may be useful in a disseminated situation.
Stegmayr
B G
BG
Department of Internal Medicine, University Hospital, Norrlands Universitets Sjukhus, Umeå, Sweden.
D000900:Anti-Bacterial Agents; D001781:Blood Component Removal; D006801:Humans; D007163:Immunosorbent Techniques; D009102:Multiple Organ Failure / Q000628:therapy*; D010951:Plasma Exchange; D011112:Polymyxin B; D018805:Sepsis / Q000628:therapy*; D012772:Shock, Septic / Q000628:therapy
D000900:Anti-Bacterial Agents; D011112:Polymyxin B